Organicell Regenerative Medicine, Inc.
OCEL · OTC
10/31/2024 | 10/31/2023 | 10/31/2022 | 10/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 1.4% | -29.8% | 16% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 81.7% | 88.9% | 88.4% | 90.2% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -115.1% | -133.1% | -125.8% | -226.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -101.8% | -153.3% | -137.9% | -229% |
| EPS Diluted | -0.74 | -0.99 | -1.57 | -2.42 |
| % Growth | 25.3% | 36.9% | 35.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |